Metastatic Triple-Negative Breast Carcinoma Clinical Trials

47 clinical trials for Metastatic Triple-Negative Breast Carcinoma across international registries, including 18 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer — RECRUITING · PHASE1
• Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer — RECRUITING · PHASE2
• DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs — RECRUITING · PHASE2
• Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer — RECRUITING · PHASE1
• A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer — RECRUITING · PHASE2
• Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer — RECRUITING · PHASE2
• Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer — RECRUITING · PHASE1
• Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy — RECRUITING · PHASE2
• Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors — RECRUITING · PHASE1
• Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer — RECRUITING · PHASE2
• A Study of Pembrolizumab and Cryoablation in People With Breast Cancer — RECRUITING · PHASE1
• Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer — RECRUITING · PHASE2
• High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer — RECRUITING · PHASE2
• Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer — RECRUITING · PHASE1
• Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer — RECRUITING
• Neratinib in Combination With Ruxolitinib in Patients With mTNBC — RECRUITING · PHASE1
• Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment — RECRUITING · NA
• Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS — RECRUITING · PHASE1
• Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer — SUSPENDED · PHASE1
• A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE2
• Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV — ACTIVE_NOT_RECRUITING · PHASE1
• Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases — COMPLETED · PHASE2
• Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases — TERMINATED · PHASE1
• Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in Metastatic Triple Negative Breast Cancer — TERMINATED
• AMTEC IIT: Phase 2 Multiarm Study in TNBC — TERMINATED · PHASE2
• NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy — ACTIVE_NOT_RECRUITING · PHASE1
• The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC — COMPLETED · PHASE1
• A Compassionate Use Study of Leronlimab in Breast Cancer — TERMINATED
• Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer — WITHDRAWN · PHASE1
• Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer — COMPLETED · PHASE1
• Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer — TERMINATED · PHASE1
• INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study — ACTIVE_NOT_RECRUITING · PHASE2
• Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer — WITHDRAWN · PHASE2
• Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer — COMPLETED · PHASE2
• Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer — COMPLETED · PHASE1
• Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer — TERMINATED · PHASE1
• ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer — WITHDRAWN · PHASE1
• Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer — COMPLETED · PHASE1
• Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer — WITHDRAWN · PHASE1
• SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer — WITHDRAWN · PHASE1
• M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer — TERMINATED · PHASE1
• Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies — TERMINATED · PHASE1
• Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast Cancer — OTHER · PHASE2
• Expanded Access for IMMU-132 — OTHER

Refine this search